Saturday, November 03, 2018 4:00:17 PM
Personally since I am no longer on the front lines as a Wall St analyst or money manager I do NOT make price predictions or market predictions publicly (maybe on very rare occasions to some really close friends) : unless your livelihood depends on it.
For the originator nothing but FEAST of Bravos OR FAMINE with personal diatribes/insults.
Fortunately we have JL who has given us his eye opening exposes on so many fronts: He's the Real McCoy.
So I've proved it to myself (is all that really matters) during close to 50 years of front line investing always growing/adjusting one's skillsets given the ACCELERATING dynamics we live in.
As for AMRN I have always felt it could be the next Lipitor.
JL cemented this potentiality for us.
So I've found since the 9/11 event it's never wise to go out on a limb although that WAS my nature.
Since then, so much MAYHEM the world has to contend with: LOTS of big cliffhangers worldwide now.
SO LETS NOT GET AHEAD OF OURSELVES AND TAKE THIS ONE STEP AT A TIME.
JL has clearly done WONDERS here but please don't go overboard where it doesn't require it.
DIFFERENT STROKES FOR DIFFERENT FOLKS.
For the originator nothing but FEAST of Bravos OR FAMINE with personal diatribes/insults.
Fortunately we have JL who has given us his eye opening exposes on so many fronts: He's the Real McCoy.
So I've proved it to myself (is all that really matters) during close to 50 years of front line investing always growing/adjusting one's skillsets given the ACCELERATING dynamics we live in.
As for AMRN I have always felt it could be the next Lipitor.
JL cemented this potentiality for us.
So I've found since the 9/11 event it's never wise to go out on a limb although that WAS my nature.
Since then, so much MAYHEM the world has to contend with: LOTS of big cliffhangers worldwide now.
SO LETS NOT GET AHEAD OF OURSELVES AND TAKE THIS ONE STEP AT A TIME.
JL has clearly done WONDERS here but please don't go overboard where it doesn't require it.
DIFFERENT STROKES FOR DIFFERENT FOLKS.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
